Project Grant R21CA274416
Award Date
9/14/23
Completion Date
8/31/25
Dollars Obligated
$442K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award of $1,126,905.00 from the National Cancer Institute (NCI) under the Cancer Centers Support Grants program (CFDA 93.397) supports research on the role of immunosuppression in the tumor microenvironment in Hispanic/Latino patients with breast cancer. The award is held by the University of Southern California (USC) and will be conducted in Los Angeles, CA from August 1, 2024 to July 31, 2026. The funded research aims to advance understanding of cancer biology,...
The University of Southern California (USC) received a $613,220 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award will fund a comprehensive investigation of the contribution of germline copy number variations (CNVs) to the risk of aggressive prostate cancer in men of African and European ancestry. The project will leverage existing genome-wide association, whole-exome sequencing, and whole-genome...
The National Cancer Institute (NCI) awarded a $220,018 Project Grant under the Cancer Treatment Research Program (CFDA 93.395) to the University of Louisville. The grant will fund research to determine whether chemotherapy-induced changes in mitochondrial function and dynamics in hematopoietic stem and progenitor cells (HSPCs) contribute to the development of pro-metastatic myeloid cells. The study aims to investigate the role of mitochondrial reactive oxygen species (ROS) production and...
The University of Southern California (USC) was awarded a $915,936 Project Grant from the U.S. Department of Defense's Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research to investigate SETD2 deficiency as a therapeutic target to upregulate viral mimicry for treating aggressive clear cell renal cell carcinoma in patients. This award is part of the program's focus on cancer, neurological disorders, and other health...
The University of Southern California (USC) was awarded a $221,904 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant will fund the "ADVANCE Cancer Health Disparities Research (CHDR) Training Program" at USC's Department of Population and Public Health Sciences. The program aims to enhance the knowledge, skills, and capacity of pre-doctoral students in minority health, cancer health...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $531,379 to the University of California, Los Angeles (UCLA) to investigate mitochondrial networks as a critical determinant of response to antibody drug conjugates (ADCs) in advanced/metastatic non-small cell lung cancer (NSCLC). The 5-year project aims to profile mitochondrial network structure and function in NSCLC cell lines, xenografts, patient-derived xenografts, and patient tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $172,013 to support the research work of a pediatric oncologist at the University of Colorado-Denver over the period of September 19, 2024 to August 31, 2029. The funded research aims to improve outcomes for children with acute lymphoblastic leukemia, particularly those who experience disease relapse, through the incorporation of novel targeted therapies into treatment regimens. The...
The Project Grant award of $300,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support a study on the epidemiology of the gut-liver axis and its relationship to hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The study aims to expand the existing Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort by enrolling approximately 1,000 participants with liver cirrhosis, with a focus on...
This $1,113,749 Project Grant awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the University of Southern California (USC) supports the development of Synthetic Immune Receptor T (SIR-T) cells targeting the B7-H3 protein for the treatment of renal cancer. The grant, which commenced on September 15, 2023, will fund a 3-year research project to explore this novel immunotherapeutic approach for addressing renal cancer. As a leading private research...
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...